Acute Unilateral Vestibulopathy and Corticosteroid Treatment

• Status: Terminated
• Trial end date: 2021-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized placebo controlled trial on patients suffering from acute unilateral vestibulopathy. Patients will be randomized into 3 arms; 1) Placebo only, 2) Short corticosteroid treatment (3days) 3) Longer corticosteroid treatment (11 days).

Vestibular function as well as subjective symptoms will be estimated in the acute stage and regularly up to one year after the debut.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lund University
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• definite unilateral vestibulopathy

• no pathological HINTS (examination criteria in acute vestibular syndrome)

• capable of making their own decisions

Exclusion Criteria:

• tinnitus or hearing loss with same debut as vertigo

• history of bleeding peptic ulcer

• glaucoma

• pregnancy or non-acceptance to use anticonception measures during 13 days after debut

• high blood pressure >180 systolic, 105, diastolic

• ketoacidosis with a Base Excess >=2

• psychic disorder (not including mild depression)

• serious infection (neutropenia, tuberculosis)

• chronic otitis

• history of vertiginous disease; Ménière, Vertiginous migraine, atypical BPPV